目的 探讨术前新辅助化疗的安全性和临床意义.方法 2002年8月～2009年12月采用术前新辅助化疗加手术治疗Ⅱ、Ⅲ期非小细胞肺癌200例.化疗方案为CTX+ADM+DDP方案30例,MMC+DDP方案行支气管动脉灌注20例,NVB+DDP方案150例;122例化疗2个周期后手术,78例化疗1个周期后手术.结果 手术切除198例,其中姑息切除3例,切除率99.0%,手术探查2例.37例术后发生心肺并发症,并发症发生率为18.5%,无手术死亡.术后1、3、5年生存率分别为80.5%、50.5%和28.0%.结论 术前新辅助化疗安全、可行,有利于提高综合治疗的疗效.%Objective To study safety and clinical significance of neoadjuvant chemotherapy plus operation. Methods Two hundreds patients with Stage Ⅱ or Ⅲ NSCLC were treated with neoadjuvant chemotherapy plus operation from August,2002 to December, 2009. Cyclophosphamide, Adriamycin and cisplatin was given to 30 patients. Mitomycin, cisplatin was infused through bronchial artery in 20 patients. 150 patients were treated with navelbine and cisplatin. 78 patients received operation after one cycle chemotherapy. 122 pations under went operation after two chemotherapy. Results lung neoplasm was excised radically in 195 patients, 3 patients under went palliative excision, surgical exploration was done in 2 patients, excision rate of lung neoplasm was 99.0％. Pulmonary and cardiac complication ocurred in 37 patients, complication incidence was 18.5％. There is no operation related death. Post operational 1,3 and 5 years survival rate were 80.5％ ,50.5％ and 28.0％ respectively. Conclusion neoadjuvant chemotherapy is safe, feasible and conducive to inproving on therapeutic efficacy of comprehensive treatment.
展开▼
